Related Experiment Videos

Carbamazepine-induced hepatorenal failure in a child

M R Haase1

  • 1Department of Pediatric Pharmacy Practice, Medical University of South Carolina, Charleston, USA.

Pharmacotherapy
|May 20, 1999
PubMed

Insights

Carbamazepine can cause serious liver and kidney damage in children, even leading to death. Promptly stopping the medication can restore normal organ function, highlighting the importance of monitoring for adverse effects.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology
  • Toxicology

Background:

  • Carbamazepine is a primary antiepileptic drug for managing various seizure disorders in children.
  • Common adverse events include neurological, dermatological (Stevens-Johnson syndrome), and hematological toxicities.
  • Less frequent but severe hepatic and renal adverse effects pose a significant risk, potentially leading to fatal outcomes.

Observation:

  • A pediatric case study involved a 6-year-old boy treated with carbamazepine for partial seizures.
  • The patient developed severe hepatorenal failure during carbamazepine therapy.
  • This adverse event highlights a critical, though less common, toxicity profile of the drug.

Findings:

  • Discontinuation of carbamazepine therapy led to the complete resolution of hepatorenal dysfunction.
  • The patient's liver and kidney function normalized within a two-week period after drug cessation.
  • This suggests a direct causal link between carbamazepine and the observed hepatorenal failure.

Implications:

  • Clinicians should maintain a high index of suspicion for hepatorenal toxicity in pediatric patients on carbamazepine.
  • Early recognition and drug withdrawal are crucial for managing carbamazepine-induced hepatorenal failure.
  • This case underscores the need for vigilant monitoring of liver and kidney function in children receiving carbamazepine, especially for less common but severe adverse effects.

Related Concept Videos